Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

A recent study revealed that bevacizumab (Avastin) provides survival benefits in patients with colorectal cancer (CRC) for ...

Amgen’s LUMAKRAS (sotorasib) and Vectibix (panitumumab) combination has received approval from the US Food and Drug Administration (FDA) to treat adults with Kirsten rat sarcoma virus gene (KRAS) ...

Amgen receives US FDA approval for Lumakras in combo with Vectibix for chemorefractory KRAS G12C-mutated metastatic colorectal cancer: Thousand Oaks, California Monday, January 20 ...

Amgen has inaugurated its new drug substance facility in the US after announcing a $1bn further expansion at the North ...

The crossover of the bevacizumab and panitumumab survival curves in the PARADIGM study: A clue to time-related effects of bevacizumab on the risk of tumor progression. Risk of peritoneal recurrence ...

Researchers identified the enzyme CMPK2 as a possible target for therapies aiming to prevent metabolic dysfunction-associated ...

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

The Sackler family, owners of Purdue Pharma, reached a $7.4 billion settlement to resolve mass opioid litigation. The Department of Justice filed a civil lawsuit against Walgreens over allegations it ...

We recently published a list of Bitcoin Miners, Quantum Computing Lead Rally: A Look at Wednesday’s Top 10 Gainers. In this article, we are going to take a look at where Tempus AI, Inc (NASDAQ ...

Secondly, the goal is to combine this drug with other drugs such as mirdametinib noted above and another drug by the name of Vectibix [panitumumab] marketed by Amgen (AMGN). The risk here is that ...

The approval is backed by Amgen’s (AMGN) CodeBreaK 300 trial, in which patients on sotorasib 960 mg/panitumumab recorded over three months of median survival benefit without cancer progression ...